Capecitabine A pre-prodrug of 5-fluorouracil Product Overview Product Name: Capecitabine Alternate Name/Synonyms: Pentyl[1-(3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl)- 5-fluoro-2-oxo-1H-pyrimidin- 4-yl]aminomethanoate; captabin; Ro 09-1978; Xabine Description: A pre-prodrug of 5-fluorouracil (5-FU). After oral uptake, capecitabine is first metabolized to 5′-deoxy-5-fluorocytidine (5′-DFCR), which occurs mainly in the liver by carboxyl-esterase. The metabolite is converted to 5′-deoxy-5-fluoro-uridine (5′-DFUR) by cytidine deaminase in liver and tumor tissue. Then 5′-DFUR is converted to 5-FU intracellularly by thymidine phosphorylase, which is often expressed in tumor tissue. Peptide Sequence: N/A Appearance: White to off-white solid Formulation: N/A CAS Number: 154361-50-9 Molecular Formula: C₁₅H₂₂FN₃O₆ Molecular Weight: 359.35 Purity: ≥99% by HPLC Solubility:DMSO (100 mg/ml) or EtOH (10 mg/ml) Storage Temp.: -20°C Shipping Conditions: gel pack Handling: Protect from air and moisture SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O InChi: InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1 InChi Key: GAGWJHPBXLXJQN-UORFTKCHSA-N PubChem CID: 60953 MDL Number: MFCD00930626 USAGE: For Research Use Only! Not For Use in Humans.
Capecitabine A pre-prodrug of 5-fluorouracil Product Overview Product Name: Capecitabine Alternate Name/Synonyms: Pentyl[1-(3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl)- 5-fluoro-2-oxo-1H-pyrimidin- 4-yl]aminomethanoate; captabin; Ro 09-1978; Xabine Description: A pre-prodrug of 5-fluorouracil (5-FU). After oral uptake, capecitabine is first metabolized to 5′-deoxy-5-fluorocytidine (5′-DFCR), which occurs mainly in the liver by carboxyl-esterase. The metabolite is converted to 5′-deoxy-5-fluoro-uridine (5′-DFUR) by cytidine deaminase in liver and tumor tissue. Then 5′-DFUR is converted to 5-FU intracellularly by thymidine phosphorylase, which is often expressed in tumor tissue. Peptide Sequence: N/A Appearance: White to off-white solid Formulation: N/A CAS Number: 154361-50-9 Molecular Formula: C₁₅H₂₂FN₃O₆ Molecular Weight: 359.35 Purity: ≥99% by HPLC Solubility:DMSO (100 mg/ml) or EtOH (10 mg/ml) Storage Temp.: -20°C Shipping Conditions: gel pack Handling: Protect from air and moisture SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O InChi: InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1 InChi Key: GAGWJHPBXLXJQN-UORFTKCHSA-N PubChem CID: 60953 MDL Number: MFCD00930626 USAGE: For Research Use Only! Not For Use in Humans.
C-2799 Capecitabine, >99% [Capecitabin] [Capecitibine] [Capecytabine] [Capiibine] [Captabin] [Caxeta] [Ro 09-1978] [Xabine] [Xeloda] M.W. 359.35 C15H22FN3O6 [154361-50-9] M.I. 14: 1754 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 12.5 mg/mL with slight warming; soluble in water at 2 mg/mL with slight warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Capecitabine is a pre-prodrug of 5-fluorouracil (5-FU). After oral uptake, capecitabine is first metabolized to 5′-deoxy-5-fluorocytidine (5′-DFCR), which happens mainly in the liver by carboxyl-esterase. The metabolite is converted to 5′-deoxy-5-fluoro-uridine (5′-DFUR) by cytidine deaminase in liver and tumor tissue. Then 5′-DFUR is converted to 5-FU intracellularly by thymidine phosphorylase, which is often expressed in tumor tissue. Miwa, M., et al. “Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.” Eur. J. Cancer 34: 1274-1281 (1998). •Capecitabine inhibits tumor growth by incorporation of 5-FU into RNA and DNA and inhibition of thymidylate synthase. Schellens, J.H. “Capecitabine.” Oncologist 12: 152-155 (2007). •Capecitabine is the active ingredient in the drug sold under the trade name Xeloda®. This drug has been approved in at least one country for use in patients with metastatic breast and colorectal cancers. NOTE: The capecitabine product sold by LC Laboratories is NOT Xeloda®, and is NOT for human use. •Other CAS numbers previously assigned to capecitabine, 158798-73-3 and 958887-39-3, have been deleted by CAS and are no longer in use. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use./b>. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses
货号： C-2799-10 g 产品名称： Capecitabine 品牌： LC 规格： 10 g
C-2799 Capecitabine, >99% [Capecitabin] [Capecitibine] [Capecytabine] [Capiibine] [Captabin] [Caxeta] [Ro 09-1978] [Xabine] [Xeloda] M.W. 359.35 C15H22FN3O6 [154361-50-9] M.I. 14: 1754 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 12.5 mg/mL with slight warming; soluble in water at 2 mg/mL with slight warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Capecitabine is a pre-prodrug of 5-fluorouracil (5-FU). After oral uptake, capecitabine is first metabolized to 5′-deoxy-5-fluorocytidine (5′-DFCR), which happens mainly in the liver by carboxyl-esterase. The metabolite is converted to 5′-deoxy-5-fluoro-uridine (5′-DFUR) by cytidine deaminase in liver and tumor tissue. Then 5′-DFUR is converted to 5-FU intracellularly by thymidine phosphorylase, which is often expressed in tumor tissue. Miwa, M., et al. “Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.” Eur. J. Cancer 34: 1274-1281 (1998). •Capecitabine inhibits tumor growth by incorporation of 5-FU into RNA and DNA and inhibition of thymidylate synthase. Schellens, J.H. “Capecitabine.” Oncologist 12: 152-155 (2007). •Capecitabine is the active ingredient in the drug sold under the trade name Xeloda®. This drug has been approved in at least one country for use in patients with metastatic breast and colorectal cancers. NOTE: The capecitabine product sold by LC Laboratories is NOT Xeloda®, and is NOT for human use. •Other CAS numbers previously assigned to capecitabine, 158798-73-3 and 958887-39-3, have been deleted by CAS and are no longer in use. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use./b>. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses
C-2799 Capecitabine, >99% [Capecitabin] [Capecitibine] [Capecytabine] [Capiibine] [Captabin] [Caxeta] [Ro 09-1978] [Xabine] [Xeloda] M.W. 359.35 C15H22FN3O6 [154361-50-9] M.I. 14: 1754 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 12.5 mg/mL with slight warming; soluble in water at 2 mg/mL with slight warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Capecitabine is a pre-prodrug of 5-fluorouracil (5-FU). After oral uptake, capecitabine is first metabolized to 5′-deoxy-5-fluorocytidine (5′-DFCR), which happens mainly in the liver by carboxyl-esterase. The metabolite is converted to 5′-deoxy-5-fluoro-uridine (5′-DFUR) by cytidine deaminase in liver and tumor tissue. Then 5′-DFUR is converted to 5-FU intracellularly by thymidine phosphorylase, which is often expressed in tumor tissue. Miwa, M., et al. “Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.” Eur. J. Cancer 34: 1274-1281 (1998). •Capecitabine inhibits tumor growth by incorporation of 5-FU into RNA and DNA and inhibition of thymidylate synthase. Schellens, J.H. “Capecitabine.” Oncologist 12: 152-155 (2007). •Capecitabine is the active ingredient in the drug sold under the trade name Xeloda®. This drug has been approved in at least one country for use in patients with metastatic breast and colorectal cancers. NOTE: The capecitabine product sold by LC Laboratories is NOT Xeloda®, and is NOT for human use. •Other CAS numbers previously assigned to capecitabine, 158798-73-3 and 958887-39-3, have been deleted by CAS and are no longer in use. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use./b>. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses
货号： C-2799-25 g 产品名称： Capecitabine 品牌： LC 规格： 25 g
C-2799 Capecitabine, >99% [Capecitabin] [Capecitibine] [Capecytabine] [Capiibine] [Captabin] [Caxeta] [Ro 09-1978] [Xabine] [Xeloda] M.W. 359.35 C15H22FN3O6 [154361-50-9] M.I. 14: 1754 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 12.5 mg/mL with slight warming; soluble in water at 2 mg/mL with slight warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Capecitabine is a pre-prodrug of 5-fluorouracil (5-FU). After oral uptake, capecitabine is first metabolized to 5′-deoxy-5-fluorocytidine (5′-DFCR), which happens mainly in the liver by carboxyl-esterase. The metabolite is converted to 5′-deoxy-5-fluoro-uridine (5′-DFUR) by cytidine deaminase in liver and tumor tissue. Then 5′-DFUR is converted to 5-FU intracellularly by thymidine phosphorylase, which is often expressed in tumor tissue. Miwa, M., et al. “Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.” Eur. J. Cancer 34: 1274-1281 (1998). •Capecitabine inhibits tumor growth by incorporation of 5-FU into RNA and DNA and inhibition of thymidylate synthase. Schellens, J.H. “Capecitabine.” Oncologist 12: 152-155 (2007). •Capecitabine is the active ingredient in the drug sold under the trade name Xeloda®. This drug has been approved in at least one country for use in patients with metastatic breast and colorectal cancers. NOTE: The capecitabine product sold by LC Laboratories is NOT Xeloda®, and is NOT for human use. •Other CAS numbers previously assigned to capecitabine, 158798-73-3 and 958887-39-3, have been deleted by CAS and are no longer in use. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use./b>. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses
C-2799 Capecitabine, >99% [Capecitabin] [Capecitibine] [Capecytabine] [Capiibine] [Captabin] [Caxeta] [Ro 09-1978] [Xabine] [Xeloda] M.W. 359.35 C15H22FN3O6 [154361-50-9] M.I. 14: 1754 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 12.5 mg/mL with slight warming; soluble in water at 2 mg/mL with slight warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Capecitabine is a pre-prodrug of 5-fluorouracil (5-FU). After oral uptake, capecitabine is first metabolized to 5′-deoxy-5-fluorocytidine (5′-DFCR), which happens mainly in the liver by carboxyl-esterase. The metabolite is converted to 5′-deoxy-5-fluoro-uridine (5′-DFUR) by cytidine deaminase in liver and tumor tissue. Then 5′-DFUR is converted to 5-FU intracellularly by thymidine phosphorylase, which is often expressed in tumor tissue. Miwa, M., et al. “Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.” Eur. J. Cancer 34: 1274-1281 (1998). •Capecitabine inhibits tumor growth by incorporation of 5-FU into RNA and DNA and inhibition of thymidylate synthase. Schellens, J.H. “Capecitabine.” Oncologist 12: 152-155 (2007). •Capecitabine is the active ingredient in the drug sold under the trade name Xeloda®. This drug has been approved in at least one country for use in patients with metastatic breast and colorectal cancers. NOTE: The capecitabine product sold by LC Laboratories is NOT Xeloda®, and is NOT for human use. •Other CAS numbers previously assigned to capecitabine, 158798-73-3 and 958887-39-3, have been deleted by CAS and are no longer in use. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use./b>. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses
货号： C0162-1 g 产品名称： Capecitabine 品牌： LKT 规格： 1 g 三周到货 生化试验
Capecitabine Description A chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. A prodrug that is enzymatically converted to 5-fluorouracil in the tumor where it inhibits DNA synthesis and slows growth of tumor tissue. Specifications Cas No. 154361-50-9 Product ID C0162 Product Name Capecitabine Formula Wt. 359.35 Store Temp Ambient References Fischer, D. S. The Cancer Chemotherapy Handbook (6th Edition). Mosby.
Capecitabine Description A chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. A prodrug that is enzymatically converted to 5-fluorouracil in the tumor where it inhibits DNA synthesis and slows growth of tumor tissue. Specifications Cas No. 154361-50-9 Product ID C0162 Product Name Capecitabine Formula Wt. 359.35 Store Temp Ambient References Fischer, D. S. The Cancer Chemotherapy Handbook (6th Edition). Mosby.
货号： C0162-5 g 产品名称： Capecitabine 品牌： LKT 规格： 5 g 三周到货 生化试验
Capecitabine Description A chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. A prodrug that is enzymatically converted to 5-fluorouracil in the tumor where it inhibits DNA synthesis and slows growth of tumor tissue. Specifications Cas No. 154361-50-9 Product ID C0162 Product Name Capecitabine Formula Wt. 359.35 Store Temp Ambient References Fischer, D. S. The Cancer Chemotherapy Handbook (6th Edition). Mosby.
Capecitabine-d8 Cayman Chemical Item Number 10010685 Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5′-deoxy-5-fluorocytidine (5′-DFCR) and 5′-deoxy-5-fluorouridine (5′-DFUR), to form 5-flyorouracil. Formal Name 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl)]-cytidine-d8 Molecular Formula C15H22D8FN3O6 Formula Weight 367.4 Formulation A crystalline solid Purity ≥99% deuterated forms (d1-d8) Stability 1 year Storage 4°C Shipping Wet ice in continental US; may vary elsewhere SMILES CC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])OC(NC(C(F)=CN1[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)=NC1=O)=O InCHI Code 1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1/i3D2,4D2,5D2,6D2 InCHI Key GAGWJHPBXLXJQN-WSMAYNAZSA-N
Capecitabine-d8 Cayman Chemical Item Number 10010685 Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5′-deoxy-5-fluorocytidine (5′-DFCR) and 5′-deoxy-5-fluorouridine (5′-DFUR), to form 5-flyorouracil. Formal Name 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl)]-cytidine-d8 Molecular Formula C15H22D8FN3O6 Formula Weight 367.4 Formulation A crystalline solid Purity ≥99% deuterated forms (d1-d8) Stability 1 year Storage 4°C Shipping Wet ice in continental US; may vary elsewhere SMILES CC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])OC(NC(C(F)=CN1[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)=NC1=O)=O InCHI Code 1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1/i3D2,4D2,5D2,6D2 InCHI Key GAGWJHPBXLXJQN-WSMAYNAZSA-N
Capecitabine-d11 Cayman Chemical Item Number 10010681 Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5′-deoxy-5-fluorocytidine (5′-DFCR) and 5′-deoxy-5-fluorouridine (5′-DFUR), to form 5-flyorouracil. Formal Name 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl)]-cytidine-d11 Molecular Formula C15H11D11FN3O6 Formula Weight 370.4 Formulation A crystalline solid Purity ≥99% deuterated forms (d1-d11) Stability 1 year Storage 4°C Shipping Wet ice in continental US; may vary elsewhere SMILES CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)C(O)C1O InCHI Code 1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1/i1D3,3D2,4D2,5D2,6D2 InCHI Key GAGWJHPBXLXJQN-XSFNBKHLSA-N
Capecitabine-d11 Cayman Chemical Item Number 10010681 Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5′-deoxy-5-fluorocytidine (5′-DFCR) and 5′-deoxy-5-fluorouridine (5′-DFUR), to form 5-flyorouracil. Formal Name 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl)]-cytidine-d11 Molecular Formula C15H11D11FN3O6 Formula Weight 370.4 Formulation A crystalline solid Purity ≥99% deuterated forms (d1-d11) Stability 1 year Storage 4°C Shipping Wet ice in continental US; may vary elsewhere SMILES CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)C(O)C1O InCHI Code 1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1/i1D3,3D2,4D2,5D2,6D2 InCHI Key GAGWJHPBXLXJQN-XSFNBKHLSA-N
货号： 10487-1 产品名称： Capecitabine 品牌： Cayman 规格： 1 g 3周
Capecitabine Cayman Chemical Item Number 10487 Description 5-Fluorouracil (5-FU) is a pyrimidine analog which noncompetitively inhibits thymidylate synthase, interfering with DNA synthesis. It has been used for the treatment of cancer for several decades. Capecitabine is a fluoropyrimidine carbamate which acts as a prodrug, being enzymatically converted to 5-FU by enzymes concentrated in the liver and in cancer tissue.1↗ The selective localization of these processing enzymes, and in particular, thymidine phosphorylase in tumor tissues, targets the production of the active product, 5-FU, in cancer cells.1↗ Synonyms Xeloda®,Ro 09-1978 Formal Name 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine CAS Number 154361-50-9 Molecular Formula C15H22FN3O6 Formula Weight 359.4 Formulation A crystalline solid Purity ≥98% Stability 2 years Storage -20°C Shipping Room temperature in continental US; may vary elsewhere SMILES O=C1N([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)C=C(F)C(NC(OCCCCC)=O)=N1 InCHI Code 1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1 InCHI Key GAGWJHPBXLXJQN-UORFTKCHSA-N -20°C
货号： 10487-10 产品名称： Capecitabine 品牌： Cayman 规格： 10 g 3周
Capecitabine Cayman Chemical Item Number 10487 Description 5-Fluorouracil (5-FU) is a pyrimidine analog which noncompetitively inhibits thymidylate synthase, interfering with DNA synthesis. It has been used for the treatment of cancer for several decades. Capecitabine is a fluoropyrimidine carbamate which acts as a prodrug, being enzymatically converted to 5-FU by enzymes concentrated in the liver and in cancer tissue.1↗ The selective localization of these processing enzymes, and in particular, thymidine phosphorylase in tumor tissues, targets the production of the active product, 5-FU, in cancer cells.1↗ Synonyms Xeloda®,Ro 09-1978 Formal Name 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine CAS Number 154361-50-9 Molecular Formula C15H22FN3O6 Formula Weight 359.4 Formulation A crystalline solid Purity ≥98% Stability 2 years Storage -20°C Shipping Room temperature in continental US; may vary elsewhere SMILES O=C1N([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)C=C(F)C(NC(OCCCCC)=O)=N1 InCHI Code 1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1 InCHI Key GAGWJHPBXLXJQN-UORFTKCHSA-N -20°C
货号： 10487-5 产品名称： Capecitabine 品牌： Cayman 规格： 5 g 3周
Capecitabine Cayman Chemical Item Number 10487 Description 5-Fluorouracil (5-FU) is a pyrimidine analog which noncompetitively inhibits thymidylate synthase, interfering with DNA synthesis. It has been used for the treatment of cancer for several decades. Capecitabine is a fluoropyrimidine carbamate which acts as a prodrug, being enzymatically converted to 5-FU by enzymes concentrated in the liver and in cancer tissue.1↗ The selective localization of these processing enzymes, and in particular, thymidine phosphorylase in tumor tissues, targets the production of the active product, 5-FU, in cancer cells.1↗ Synonyms Xeloda®,Ro 09-1978 Formal Name 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine CAS Number 154361-50-9 Molecular Formula C15H22FN3O6 Formula Weight 359.4 Formulation A crystalline solid Purity ≥98% Stability 2 years Storage -20°C Shipping Room temperature in continental US; may vary elsewhere SMILES O=C1N([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)C=C(F)C(NC(OCCCCC)=O)=N1 InCHI Code 1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1 InCHI Key GAGWJHPBXLXJQN-UORFTKCHSA-N -20°C
Capecitabine Cayman Chemical Item Number 10487 Description 5-Fluorouracil (5-FU) is a pyrimidine analog which noncompetitively inhibits thymidylate synthase, interfering with DNA synthesis. It has been used for the treatment of cancer for several decades. Capecitabine is a fluoropyrimidine carbamate which acts as a prodrug, being enzymatically converted to 5-FU by enzymes concentrated in the liver and in cancer tissue.1↗ The selective localization of these processing enzymes, and in particular, thymidine phosphorylase in tumor tissues, targets the production of the active product, 5-FU, in cancer cells.1↗ Synonyms Xeloda®,Ro 09-1978 Formal Name 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine CAS Number 154361-50-9 Molecular Formula C15H22FN3O6 Formula Weight 359.4 Formulation A crystalline solid Purity ≥98% Stability 2 years Storage -20°C Shipping Room temperature in continental US; may vary elsewhere SMILES O=C1N([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)C=C(F)C(NC(OCCCCC)=O)=N1 InCHI Code 1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1 InCHI Key GAGWJHPBXLXJQN-UORFTKCHSA-N -20°C
